share_log

Watching Cabaletta Bio; Hearing Traders Circulate Cantor Fitzgerald Saying "We're Not Going To Be Spooked By This Amorphous 'FDA Is Looking Into This' Headline. We Have Accepted All Sorts Of Development Risks" Defends Buy Rating With $50 Price Target

Benzinga ·  Nov 28, 2023 12:30
Watching Cabaletta Bio; Hearing Traders Circulate Cantor Fitzgerald Saying "We're Not Going To Be Spooked By This Amorphous 'FDA Is Looking Into This' Headline. We Have Accepted All Sorts Of Development Risks" Defends Buy Rating With $50 Price Target
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment